Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Aventis Plans To Launch Genasense, Ketek and Apidra In 2004

  • News

Executive Summary

The launch of Genasense will be a key step in Aventis' plans to build its oncology franchise, Chief Operating Officer Richard Markham said Jan. 13 during the J.P. Morgan health care conference in San Francisco

You may also be interested in...



Ketek Launch Is First For Sanofi-Aventis; Merger Will Test Focus

Ketek will be the first product launch for the newly formed Sanofi-Aventis

Ketek Launch Is First For Sanofi-Aventis; Merger Will Test Focus

Ketek will be the first product launch for the newly formed Sanofi-Aventis

Aventis Apidra Clears FDA; Launch Of Fast-Acting Insulin Awaits Delivery Pen

Aventis will wait to launch the rapid-acting recombinant human insulin analog Apidra until after approval of the OptiClick pen delivery device

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet
Tags:
Latest Headlines

Recent And Upcoming FDA Advisory Committee Meetings

EMA Recommends Revoking EU Approval For Novartis’s Sickle Cell Disease Drug

EMA Backs EU Approval For Ztalmy & Pylclari; Roches Withdraws EU Filing For AMD Implant

UK In Major Move To Boost Commercial Clinical Trials & Improve Life Sciences Environment

See All
UsernamePublicRestriction

Register

PS043160

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By